What is Kailera Therapeutics 's accretion (amortization) of discounts and premiums on investments?

Kailera Therapeutics (KLRA) reported accretion (amortization) of discounts and premiums on investments of $1.23M in Q1 2026.

Accretion (amortization) of discounts and premiums on investments

StatementCash Flow Statement

SectionOperating

CategoryCapital Allocation

SignalContext dependent

VolatilityModerate

First reportedQ1 2025

Last reportedQ1 2026May 26, 2026

Reflects the yield characteristics of the investment portfolio; changes are driven by interest rate environments and bond pricing.

This reflects the non-cash adjustment for the difference between the purchase price and the par value of fixed-income se...

Common in insurance and banking sectors where large investment portfolios are held.

Metric ID: bac_accretion_amortization_investments

2 periods

	Q1 '25	Q1 '26
Value	$0.00	$1.23M

Range$0.00 – $1.23M

What is Kailera Therapeutics 's accretion (amortization) of discounts and premiums on investments?: Kailera Therapeutics (KLRA) reported accretion (amortization) of discounts and premiums on investments of $1.23M in Q1 2026.
What does accretion (amortization) of discounts and premiums on investments mean?: Non-cash adjustments to the value of investment securities held by the company.